Log in
NASDAQ:STRO

Sutro Biopharma Stock Forecast, Price & News

$11.00
+0.01 (+0.09 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.88
Now: $11.00
$11.47
50-Day Range
$8.39
MA: $10.00
$13.15
52-Week Range
$6.00
Now: $11.00
$13.91
Volume245,099 shs
Average Volume176,486 shs
Market Capitalization$394.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More
Sutro Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STRO
CUSIPN/A
CIKN/A
Phone650-392-8412

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.74 million
Book Value$4.24 per share

Profitability

Net Income$-55,740,000.00

Miscellaneous

Employees141
Market Cap$394.67 million
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
$11.00
+0.01 (+0.09 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

How has Sutro Biopharma's stock price been impacted by Coronavirus (COVID-19)?

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STRO shares have increased by 35.6% and is now trading at $11.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sutro Biopharma?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sutro Biopharma
.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Sutro Biopharma
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma Inc (NASDAQ:STRO) announced its earnings results on Monday, May, 11th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.15. The business had revenue of $7.15 million for the quarter, compared to the consensus estimate of $11.16 million. Sutro Biopharma had a negative return on equity of 53.40% and a negative net margin of 43.34%.
View Sutro Biopharma's earnings history
.

What price target have analysts set for STRO?

8 Wall Street analysts have issued 1 year price targets for Sutro Biopharma's stock. Their forecasts range from $17.00 to $21.00. On average, they expect Sutro Biopharma's share price to reach $18.83 in the next year. This suggests a possible upside of 71.2% from the stock's current price.
View analysts' price targets for Sutro Biopharma
.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Fulcrum Therapeutics (FULC), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Xeris Pharmaceuticals (XERS), AbbVie (ABBV), Aduro BioTech (ADRO) and Aldeyra Therapeutics (ALDX).

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the following people:
  • Mr. William J. Newell, CEO & Director (Age 61)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
  • Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 61)

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (10.20%), Point72 Asset Management L.P. (2.58%), Logos Global Management LP (1.56%), Barclays PLC (1.02%), Granite Point Capital Management L.P. (0.65%) and Driehaus Capital Management LLC (0.28%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, Daniel H Petree, John Gordon Freund, Merck & Co, Inc, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma
.

Which institutional investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam.
View insider buying and selling activity for Sutro Biopharma
.

Which institutional investors are buying Sutro Biopharma stock?

STRO stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Logos Global Management LP, Granite Point Capital Management L.P., Bessemer Group Inc., California Public Employees Retirement System, Trexquant Investment LP, and Goldman Sachs Group Inc.. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, Merck & Co, Inc, and William J Newell.
View insider buying and selling activity for Sutro Biopharma
.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $11.00.

How big of a company is Sutro Biopharma?

Sutro Biopharma has a market capitalization of $394.67 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is www.sutrobio.com.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.